
    
      This is a Phase 1, single-center, dose-escalations (SAD and MAD) and food effect study of
      FCN-207:

      Part 1 Single Ascending Dose (SAD) study: randomized, double-blind, placebo-controlled.

      Part 2 Food-effect study: single-dose, two-treatment (fasted vs. high-fat meal), two-sequence
      crossover design.

      Part 3 Multiple Ascending Dose (MAD) study: randomized, double-blind, placebo-controlled.
    
  